Richard Giltner
CIK: 0001460472
Associated companies
Transaction History
| UTHR | ▲ Buy | Option Exercise | 1,310 | $0 | 7/9/2026 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 1,190 | $0 | 7/25/2025 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 5,000 | $877K | 6/24/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 3,036 | $879K | 6/24/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 1,429 | $546K | 11/5/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 10,000 | $1.8M | 11/5/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 8,571 | $3.3M | 11/5/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 1,800 | $0 | 7/13/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 10,000 | $880K | 3/6/2024 | View on chart |
| UTHR | ▼ Sell | Other | 10,000 | $2.4M | 3/6/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 5,000 | $440K | 12/1/2023 | View on chart |
| UTHR | ▼ Sell | Other | 5,000 | $1.2M | 12/1/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 1,750 | $0 | 7/7/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 5,000 | $320K | 5/22/2023 | View on chart |
| UTHR | ▼ Sell | Other | 5,000 | $1.1M | 5/22/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 10,000 | $639K | 11/16/2022 | View on chart |
| UTHR | ▼ Sell | Other | 10,000 | $2.6M | 11/16/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,160 | $0 | 7/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
United Therapeutics Settles Litigation, Market Reassesses Valuation
United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.
United Therapeutics Settles Litigation, Market Reassesses Valuation. United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.